JP2001316293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001316293A5 JP2001316293A5 JP2001047695A JP2001047695A JP2001316293A5 JP 2001316293 A5 JP2001316293 A5 JP 2001316293A5 JP 2001047695 A JP2001047695 A JP 2001047695A JP 2001047695 A JP2001047695 A JP 2001047695A JP 2001316293 A5 JP2001316293 A5 JP 2001316293A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- glucosidase inhibitor
- mitiglinide
- repaglinide
- insulin secretagogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
【特許請求の範囲】
【請求項１】活性成分としてα−グルコシダーゼ阻害薬と、レパグリニド及びミチグリニドから選ばれる非スルホニルウレア系インスリン分泌促進薬のみを組み合わせてなる医薬。
【請求項２】α−グルコシダーゼ阻害薬がボグリボースである請求項１記載の医薬。
【請求項３】α−グルコシダーゼ阻害薬がアカルボースである請求項１記載の医薬。
【請求項４】α−グルコシダーゼ阻害薬がミグリトールである請求項１記載の医薬。
【請求項５】α−グルコシダーゼ阻害薬がエミグリテートである請求項１記載の医薬。
【請求項６】 α−グルコシダーゼ阻害薬の１日あたりの投与量が０．１〜５００ｍｇである請求項１記載の医薬。
【請求項７】 ボグリボースの１日あたりの投与量が０．１〜２ｍｇである請求項２記載の医薬。
【請求項８】非スルホニルウレア系インスリン分泌促進薬がレパグリニドである請求項１記載の医薬。
【請求項９】 レパグリニドの１日あたりの投与量が０．５〜１５ｍｇである請求項８記載の医薬。
【請求項１０】非スルホニルウレア系インスリン分泌促進薬がミチグリニドである請求項１記載の医薬。
【請求項１１】 ミチグリニドの１日あたりの投与量が１〜５０ｍｇである請求項１０記載の医薬。
【請求項１２】α−グルコシダーゼ阻害薬がボグリボースであり、非スルホニルウレア系インスリン分泌促進薬がレパグリニドである請求項１記載の医薬。
【請求項１３】 α−グルコシダーゼ阻害薬がボグリボースであり、非スルホニルウレア系インスリン分泌促進薬がミチグリニドである請求項１記載の医薬。
【請求項１４】糖尿病の予防・治療剤である請求項１記載の医薬。
【請求項１５】糖尿病合併症の予防・治療剤である請求項１記載の医薬。
【請求項１６】耐糖能異常の予防・治療剤である請求項１記載の医薬。
【請求項１７】 経口剤である請求項１記載の医薬。
【請求項１８】 錠剤である請求項１記載の医薬。
【請求項１９】活性成分として、レパグリニド及びミチグリニドから選ばれる非スルホニルウレア系インスリン分泌促進薬のみと組み合わせて用いられる糖尿病の予防・治療剤製造のためのα−グルコシダーゼ阻害薬の使用。
[Claims]
1. A medicament comprising a combination of an α-glucosidase inhibitor and a non-sulfonylurea insulin secretagogue selected from repaglinide and mitiglinide as active ingredients.
2. The medicament according to claim 1, wherein the α-glucosidase inhibitor is voglibose.
3. The medicament according to claim 1, wherein the α-glucosidase inhibitor is acarbose.
4. The medicament according to claim 1, wherein the α-glucosidase inhibitor is miglitol.
5. The medicament according to claim 1, wherein the α-glucosidase inhibitor is emiglitate.
6. The medicament according to claim 1, wherein the daily dose of the α-glucosidase inhibitor is 0.1 to 500 mg.
7. A medicament according to claim 2, wherein the daily dose of voglibose is 0.1 to 2 mg.
8. The medicament according to claim 1, wherein the non-sulfonylurea insulin secretagogue is repaglinide.
9. The medicament according to claim 8, wherein the daily dose of repaglinide is 0.5 to 15 mg.
10. The medicament according to claim 1, wherein the non-sulfonylurea insulin secretagogue is mitiglinide.
11. The medicament according to claim 10, wherein the daily dose of mitiglinide is 1 to 50 mg.
12. The medicament according to claim 1, wherein the α-glucosidase inhibitor is voglibose, and the non-sulfonylurea insulin secretagogue is repaglinide.
13. The medicine according to claim 1, wherein the α-glucosidase inhibitor is voglibose, and the non-sulfonylurea insulin secretagogue is mitiglinide.
14. The medicament according to claim 1, which is an agent for preventing or treating diabetes.
15. The pharmaceutical according to claim 1, wherein an agent for the prophylaxis or treatment of diabetic complications.
16. The medicament according to claim 1, which is a prophylactic / therapeutic agent for impaired glucose tolerance.
17. The medicament according to claim 1, which is an oral preparation.
18. The pharmaceutical according to claim 1, which is a tablet.
As 19. active ingredients, the use of α- glucosidase inhibitor for the prophylaxis or treatment agent manufacture of non-sulfonylurea insulin secretagogue only in combination with diabetes to be used selected from repaglinide, and mitiglinide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001047695A JP4917712B2 (en) | 2000-02-24 | 2001-02-23 | Concomitant medication |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000052297 | 2000-02-24 | ||
| JP2000-52297 | 2000-02-24 | ||
| JP2000052297 | 2000-02-24 | ||
| JP2001047695A JP4917712B2 (en) | 2000-02-24 | 2001-02-23 | Concomitant medication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001316293A JP2001316293A (en) | 2001-11-13 |
| JP2001316293A5 true JP2001316293A5 (en) | 2007-08-16 |
| JP4917712B2 JP4917712B2 (en) | 2012-04-18 |
Family
ID=26586285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001047695A Expired - Lifetime JP4917712B2 (en) | 2000-02-24 | 2001-02-23 | Concomitant medication |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4917712B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1665498A (en) * | 2002-06-28 | 2005-09-07 | 橘生药品工业株式会社 | Drug composition for blood sugar control |
| WO2004002474A1 (en) * | 2002-06-28 | 2004-01-08 | Kissei Pharmaceutical Co., Ltd. | Drug composition for prevention or inhibition of advance of diabetic complication |
| JP2004067575A (en) * | 2002-08-06 | 2004-03-04 | Yaizu Suisankagaku Industry Co Ltd | Promoter for effect of therapeutic agent for diabetes |
| EP1714648A4 (en) * | 2004-02-09 | 2010-05-26 | Aska Pharm Co Ltd | Combination drug |
| CA2605302A1 (en) * | 2005-04-20 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | Combined pharmaceutical preparation for treatment of type 2 diabetes |
| JP5678477B2 (en) | 2009-05-28 | 2015-03-04 | 旭硝子株式会社 | Optical glass |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
| JPH11130696A (en) * | 1997-08-27 | 1999-05-18 | Takeda Chem Ind Ltd | Oral sustained release preparation |
-
2001
- 2001-02-23 JP JP2001047695A patent/JP4917712B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20014519L (en) | Apomorphine and Sildenafil Preparation | |
| RU2002127804A (en) | MEDICINAL SYSTEM FOR TREATMENT OF COMPLICATIONS CONNECTED WITH DIABETES AND NEUROPATHY, AND THEIR APPLICATION | |
| CA2434484A1 (en) | Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances | |
| RU2008119454A (en) | MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS | |
| JP2002528502A5 (en) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| CA2240717A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| WO2000041504A3 (en) | Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| JP2001510795A5 (en) | ||
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| JP2004537500A5 (en) | ||
| CA2401000A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| WO2001089536A3 (en) | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders | |
| JP2003514025A5 (en) | ||
| JP2001316293A5 (en) | ||
| JP2005508963A5 (en) | ||
| JP2002540148A5 (en) | ||
| JP2002530353A5 (en) | ||
| IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
| LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| RU2002124141A (en) | APPLICATION OF MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDERS | |
| JP2005513105A5 (en) | ||
| JP2002523362A5 (en) |